Skin substitute usage in SNFs is the least visible slice of CTP and CAMP utilization, and the public data most teams rely on undercounts it by design. Medicare Part B claims capture some SNF activity, but consolidated billing, Medicare Advantage enrollment, and contracted wound groups mean a claims-only view can misstate both volume and product mix. Anyone sizing this setting from fee-for-service files is working from a fragment.
The setting also differs clinically and commercially from hospital outpatient wound centers and home visits. Wound types, payment rules, and who applies the product all shift, and each shift changes which products are used and how defensible that use is. The sections below cover why SNFs differ, which sources can see them, what patterns to expect, and how to read the numbers without overreaching.
Why Does Skin Substitute Usage in SNFs Differ From Other Care Settings?
Start with the patient. SNF residents typically carry a heavier comorbidity burden than patients who travel to an outpatient wound center, and many have limited mobility. That changes the wound-type mix: pressure ulcers make up a much larger share of the caseload, alongside diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Because product selection tracks wound type, the product mix in SNFs will not mirror the hospital outpatient mix even before payment rules enter the picture.
Payment context is the second divider. Under Medicare Part A consolidated billing, most services furnished to a resident in a covered SNF stay are bundled into the facility’s payment, and certain services are excluded from that bundle and billed separately by the provider. Once the Part A stay ends, or for residents not in a covered stay, services fall under Part B and the treating practitioner can bill under the usual rules. Since January 1, 2026, the CY 2026 Physician Fee Schedule final rule has paid most skin substitutes as incident-to supplies at a flat rate of roughly $127 per square centimeter in physician offices and hospital outpatient departments, and the CY 2027 proposed rule would keep that approach. The new product payment does not override SNF consolidated billing, so confirm the current exclusion list and how the product is billed versus the professional service. The practical point is that whether a CTP is billable, and by whom, can depend on the resident’s stay status on the date of application.
The third factor is who applies the product. Three models are common:
- Visiting wound physicians or nurse practitioners who bill independently
- Facility-employed clinicians working under the facility’s protocols and formulary
- Contracted wound care groups that cover multiple facilities and often bring their own product preferences
Each model has a different ordering path. A visiting practitioner may choose the product and supply it through a distributor. A facility-employed clinician may be constrained by purchasing decisions made above the bedside. A contracted group may standardize on a few products across dozens of buildings. For a manufacturer, that means the real decision-maker in SNFs is often a group or a purchasing function, not the individual clinician a field team usually targets.
Where Can You Find Reliable Data on Skin Substitute Utilization in SNFs?
No single source sees the whole setting. Each of the four common types has a specific blind spot.
- Medicare Part B claims files: Strong for fee-for-service volume, billed units, and spend by HCPCS code. They show what was billed to Part B, not what was applied in a bundled Part A stay, and place of service coding can blur SNF versus other facility types.
- MAC and LCD documentation: Useful for what is covered and what documentation is expected. They describe policy, not utilization, so they explain constraints rather than measure behavior.
- Real-world datasets derived from a wound care EHR: Capture clinical detail such as wound type, measurements, product applied, and care setting. Coverage depends on which practices and facilities contribute, so representativeness has to be examined.
- Manufacturer sales data: Show what shipped, usually by account or distributor. They do not show which wounds were treated, whether the product was applied, or the care setting in any consistent way.
The claims gaps that matter most
Two gaps recur. First, Part A stays bundle services, so product use inside a covered stay may leave no product-level trace in Part B files. Second, Medicare Advantage and commercial lines are largely absent from fee-for-service claims. Where a SNF population is heavily enrolled in Medicare Advantage, a fee-for-service file can understate activity substantially. The common assumption that SNF data equals Medicare claims data fails on both counts.
What a cross-setting dataset adds
A real-world dataset that records the care setting alongside product and wound type can place SNF use next to home visits and hospital-based wound centers on the same basis. The Intellicure Analytics Wound Care Industry Dashboard is built on that approach, tracking product utilization across SNFs, home visits, and hospital-based wound centers. Its value is comparability across settings, but it inherits the limits of any contributed dataset: it reflects the sites and clinicians in the data, not every facility in the country. Check current coverage and definitions on IntellicureAnalytics.ai before relying on it for a specific question.
Which Wound Types and Products Drive SNF Skin Substitute Use?
The expected divergence from hospital outpatient practice is in the wound-type mix: more pressure ulcers, relatively fewer DFUs. Whether that holds, and by how much, is an empirical question for a given dataset and period. This article does not assert specific percentages, because they should come from a named, dated analysis. Intellicure Analytics and Caroline Fife, MD have published wound care data analyses, and any share you cite for SNFs should be traced to a specific publication, year, and URL rather than carried over from general impressions.
CTPs, CAMPs, and the ranking problem
Treat CTPs and CAMPs as separate categories when analyzing the setting, since their evidence bases, coding, and coverage positions differ. Within each, distinguish high-volume products from the long tail. Then be explicit about the ranking metric, because the leader changes with it:
- By units: Favors low-cost, small-format products and frequent applications.
- By claims: Favors products used across many encounters regardless of size or price.
- By spend: Favors high-priced products, even with modest volume.
A product can rank first on units and well down the list on spend. Equating the two is a frequent misreading, and it distorts both market sizing and competitive positioning. Product Ranking Reports are most useful when they show all three views side by side.
The competitor you did not plan for
In SNFs, the alternative to a given skin substitute is often not another skin substitute. It may be a different CTP favored by a contracted wound group, a standard-of-care dressing regimen that never escalates, or NPWT. A manufacturer benchmarking only against the brand it assumes to be its rival can miss the actual substitution pattern. Setting-specific data on what was used on comparable wounds is the way to find out, and the answer often differs from what a hospital outpatient view would suggest.
How Do Coverage Policy and Audit Risk Shape SNF Usage?
Coverage for skin substitutes in DFUs and VLUs has been governed by LCDs, which set expectations for when a CTP is reasonable and necessary. The uniform DFU and VLU LCDs that all seven A/B MACs planned to implement on January 1, 2026 were withdrawn on December 24, 2025, so Novitas, CGS, and First Coast continue to apply their existing skin substitute LCDs, while other jurisdictions review claims case by case. Typical requirements include documented wound measurements over time, a defined period of standard-of-care treatment before application, and complete application records. Verify the current policy for the relevant MAC before applying any of this to a specific claim, since this area has been in flux.
Those requirements are harder to satisfy in a SNF record. Wound measurements may be taken by different staff using different methods. Standard-of-care history can be split between the facility, a prior hospital stay, and an outside practitioner. Application documentation may sit in a visiting clinician’s system rather than the facility chart. Each gap is a point where an audit can reject an otherwise appropriate application.
Pressure ulcers as the pointed question
Pressure ulcers deserve separate scrutiny. Skin substitute LCDs address DFUs and VLUs, not pressure ulcers, and the evidence base for CTPs in this indication is thinner, so use there carries more compliance exposure. Because pressure ulcers are a larger share of SNF wounds, the setting concentrates that exposure. Confirm current policy language before stating what is or is not covered, and avoid inferring coverage from the fact that a product is being used.
The defensive use of real-world evidence
Post-Market Clinical Follow-Up and real-world outcome data give manufacturers something to bring to coverage reviews and audit responses: documented measurement practice, outcomes by wound type, and evidence from the settings where the product is actually used. Evidence generated only in outpatient centers leaves a gap when reviewers ask about SNF populations.
What Are the Limitations of SNF Skin Substitute Data?
Start with selection. SNF residents are not randomized to treatment, and the reasons a clinician chose a skin substitute over a dressing are often tied to prognosis, payer status, or who happened to be visiting. Wound severity, comorbidities, and length of stay vary widely. A raw comparison of healing between products can therefore reflect who received them rather than what they did.
Endpoints are the second problem. Healing is only measurable if wounds are measured consistently, and in SNFs measurement frequency varies. Residents are discharged, transferred, hospitalized, or die before closure, and those who leave the data are rarely random. If patients with poor trajectories drop out disproportionately, closure rates among those who remain look better than reality. If the reverse happens, they look worse. Either way, the direction of bias is not obvious from the data alone.
Utilization also does not imply effectiveness. A product used widely in SNFs may be favored because of price, distributor relationships, a contracted group’s preference, or ease of storage, none of which speaks to outcomes.
A workable rule follows from this:
- Treat utilization counts as descriptive: they say what was used, not what worked.
- Treat unadjusted outcome comparisons as hypothesis-generating.
- Give weight to outcome comparisons only when they adjust for wound type, size, duration, comorbidity, and length of observation, and when they report how many patients were lost before closure.
When a decision depends on relative effectiveness, a Comparative Effectiveness Study designed with these confounders in mind is the stronger option, because it defines the cohort, endpoint, and follow-up rules before looking at results.
How Can Manufacturers, Payers, and Purchasers Use SNF Utilization Data?
Manufacturers
Build a PMCF plan that explicitly includes SNF patients rather than extrapolating from outpatient cohorts. Size the SNF market from setting-specific data, not from claims alone, given the Part A and Medicare Advantage gaps. Then map the true competitor set by wound type: other CTPs, standard-of-care regimens, and NPWT may each matter in different segments.
Payers and policy staff
Monitor SNF-specific utilization for outliers, such as facilities or contracted groups with unusual product volume, application frequency, or pressure ulcer share. Compare each against other settings for the same wound types, since a figure that looks high in isolation may be ordinary once the wound mix is accounted for. Outliers are a prompt for review, not a finding.
Provider purchasers
Value analysis committees and GPO teams can use product ranking and utilization benchmarks to see how their own purchasing compares with the field, and to ask which products are used on which wounds in comparable facilities. Rankings describe use. They are not endorsements, and no brand should be treated as recommended on the strength of its position.
Measure the SNF Setting on Its Own Terms
Skin substitute usage in SNFs has to be measured separately from other settings, with the wound mix, billing rules, and applying clinician model in view, and then read with its limits in mind: counts describe, unadjusted outcomes suggest, and only designed comparisons support a claim about effectiveness. To quantify your own product’s SNF footprint, start with the Intellicure Analytics Wound Care Industry Dashboard for cross-setting utilization, or commission a Comparative Effectiveness Study when you need adjusted outcome evidence. Learn more about our SNF wound care data and how skin subs are applied to pressure ulcers.